prostate cancer

prostate cancer
Name	Prostate cancer
Field	Oncology, Urology
Symptoms	Urinary retention; hematuria; bone pain; erectile dysfunction
Complications	Metastasis to bone, lymph nodes, spinal cord compression
Onset	Mostly age >50 years
Risks	Age, family history, race, BRCA mutations
Diagnosis	PSA test, digital rectal exam, biopsy, MRI, CT, bone scan
Treatment	Active surveillance, prostatectomy, radiotherapy, androgen deprivation therapy, chemotherapy
Prognosis	Variable; localized disease often curable; metastatic disease generally incurable

prostate cancer is a malignant neoplasm originating in the prostate gland of males, primarily affecting older adults and varying widely in clinical course from indolent to aggressive metastatic disease. It is a leading cause of cancer morbidity and mortality in men worldwide and is managed across specialties including Urology, Oncology, Radiation oncology, and Pathology. Clinical decisions integrate findings from biomarkers, imaging, histopathology, and genetic testing performed at institutions such as Mayo Clinic, Johns Hopkins Hospital, and national registries like the Surveillance, Epidemiology, and End Results program.

Overview

Prostate carcinoma most commonly arises as adenocarcinoma of the peripheral zone and demonstrates heterogeneity in behavior documented by centers including Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Historical landmarks in understanding include work by Marie Curie in radiation effects, surgical refinements attributed to surgeons at Johns Hopkins Hospital, and randomized trials conducted by cooperative groups such as the European Organisation for Research and Treatment of Cancer and National Institutes of Health. Population screening controversies feature recommendations from organizations like the United States Preventive Services Task Force, the American Urological Association, and the European Association of Urology.

Signs and symptoms

Early-stage tumors are frequently asymptomatic, detected incidentally via screening programs promoted by agencies like the American Cancer Society. Symptomatic presentations commonly involve lower urinary tract symptoms assessed in clinics affiliated with Cleveland Clinic, including urinary frequency, nocturia, weak stream, and hesitancy. Advanced disease may present with bone pain from metastases to the pelvis or vertebrae seen on scans performed at Memorial Sloan Kettering Cancer Center or Royal Marsden Hospital, pathological fractures evaluated by orthopedic oncology teams at Mayo Clinic, and neurological deficits from spinal cord compression managed in tertiary centers like Mount Sinai Hospital.

Causes and risk factors

Age is the strongest epidemiological correlate, with incidence rising markedly after 50 and peaks reported in national datasets from United Kingdom National Health Service and Centers for Disease Control and Prevention. Heritable risk involves germline variants in genes such as BRCA1, BRCA2, and mismatch repair genes identified in consortia like the International Society of Urological Pathology. Racial disparities—higher incidence and mortality among men of African descent—are documented by studies from University of Cape Town and Harvard Medical School. Environmental and occupational exposures studied by groups at World Health Organization and International Agency for Research on Cancer include dietary factors and agrochemical exposure examined in cohort studies by National Cancer Institute.

Diagnosis

Initial assessment combines prostate-specific antigen testing developed following research at Roswell Park Comprehensive Cancer Center with physical examination including digital rectal exam performed in urology clinics such as Guy's and St Thomas' NHS Foundation Trust. Multiparametric magnetic resonance imaging protocols standardized by societies like the European Society of Urogenital Radiology guide targeted biopsies performed under transrectal or transperineal approaches taught in training programs at Royal College of Surgeons. Histopathologic diagnosis relies on Gleason grading refined by consensus from the International Society of Urological Pathology and immunohistochemistry interpreted by pathology departments at institutions like Stanford Health Care.

Staging and grading

Tumor staging follows the TNM classification developed by the Union for International Cancer Control and used by cancer centers including Memorial Sloan Kettering Cancer Center; localized (T1–T2), locally advanced (T3–T4), regional nodal (N1), and distant metastatic (M1) categories guide management. Gleason score and Grade Group—standardized through collaborative efforts at Johns Hopkins Hospital—stratify histologic aggressiveness and inform risk groups endorsed by the National Comprehensive Cancer Network. Advanced molecular classifiers and genomic risk scores validated in multicenter trials at Dana-Farber Cancer Institute refine prognostication and therapeutic selection.

Treatment

Management spans active surveillance protocols established in trials at PRIAS and University of Toronto, radical prostatectomy performed at high-volume centers like Mayo Clinic with nerve-sparing techniques, external beam radiotherapy delivered in departments such as MD Anderson Cancer Center, and brachytherapy practiced at specialized units including Memorial Sloan Kettering Cancer Center. Systemic therapy for advanced disease includes androgen deprivation therapy introduced following endocrine research at Vanderbilt University Medical Center, next-generation androgen receptor pathway inhibitors approved after trials run by European Medicines Agency and Food and Drug Administration (United States), chemotherapy regimens evaluated by cooperative groups like ECOG-ACRIN, and emerging approaches such as PARP inhibitors targeting BRCA2-mutant tumors investigated in oncology centers like Royal Marsden Hospital.

Prognosis and epidemiology

Prognosis depends on stage, grade, and patient factors; localized disease treated at high-volume centers such as Johns Hopkins Hospital often yields long-term survival, whereas metastatic castration-resistant disease remains incurable in many patients despite advances tested in trials by National Cancer Institute. Global incidence and mortality trends documented by the World Health Organization and national registries show substantial geographic variation influenced by screening policies in countries including Sweden, United States, and Japan. Public health initiatives by organizations like the American Cancer Society and Cancer Research UK focus on early detection, equity in care, and research funding for novel therapeutics.

Category:Urologic neoplasms